Dr. med. Kathrin Schmidig
Finch 302 Gilead
May 24, 2017A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Sub...
Clinical Studies - May 24, 2017 - Sep 26, 2018
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Hutz Carina Liane, Bartz-Batliner Mira, Schmidig Kathrin
BIOBIO
Feb 14, 2017A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients with Rheumatoid Arthritis to a Specific Biologic Mode of Action
Clinical Studies - Feb 14, 2017 - Aug 16, 2018
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Hutz Carina Liane, Bartz-Batliner Mira, Schmidig Kathrin
BI1199.214 Senscis
Aug 9, 2016A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’(SSc-ILD). A trial to compare nintedanib...
Clinical Studies - Aug 9, 2016 - Sep 8, 2017
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Bartz-Batliner Mira, Hutz Carina Liane, Schmidig Kathrin
BAY16277 RISE
May 13, 2016A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) Evaluierung der Wirksamkeit und Sicherheit einer 52-wöchigen Behandlung m...
Clinical Studies - May 13, 2016 - Apr 28, 2019
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Bartz-Batliner Mira, Hutz Carina Liane, Schmidig Kathrin
SpA: AIN 457F2320
Aug 5, 2015A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading regimen to assess efficacy, safety, and tolerability up to 2 years in patients with active ankylo...
Clinical Studies - Aug 5, 2015 - Aug 16, 2018
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Bartz-Batliner Mira, Hutz Carina Liane, Schmidig Kathrin
aSCore: LONG-TERM EXPERIENCE WITH ABATACEPT SC IN ROUTINE CLINICAL
May 6, 2015STUDY DESIGN Overview of Study Design This is a non-interventional, multicenter, study consisting of 2 prospective cohorts of patients diagnosed with moderate to severe active RA and initiated/treated with abatacept SC. In some countries, patients ca...
Clinical Studies - May 6, 2015 - Oct 6, 2017
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Schmidig Kathrin, Bartz-Batliner Mira, Hutz Carina Liane
PsoA: A phase III, randomized, double-blind, placebo-controlled multicenter
Aug 20, 2014Study to demonstrate the efficacy at 24 weeks and to assess the long term efficacy, safety and tolerability of secukinumab in Active Psoriatic Arthritis
Clinical Studies - Aug 20, 2014 - Aug 16, 2018
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Bartz-Batliner Mira, Hutz Carina Liane, Schmidig Kathrin
RICE: An open label, randomized study to compare the efficacy of Certolizumab pegol (CZP) plus a dynamic or fixed dose treatment strategy in patients with Rheumatoid Arthritis, a phase II study
Jun 7, 2014randomisierte Studie bei fortgeschrittener rheumatoider Arthritis mit Certolizumab, Standardtherapie DMARD/Prednison plus Certolizumab vs Therapieeskalation DMARD/Prednison mit Certolizumab und Gelenksinfiltration.
Clinical Studies - Jun 7, 2014 - Aug 31, 2018
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Bartz-Batliner Mira, Schmidig Kathrin, Hutz Carina Liane